Physician profile
Anil Tulpule
NPI 1710913249
$78,788.21
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,947 · 2020: $189 · 2021: $19K · 2022: $24K · 2023: $30K · 2024: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Travel and Lodging: $3,482 · Food and Beverage: $1,517 · Consulting Fee: $975.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,350.00 |
| Travel and Lodging | $3,481.78 |
| Food and Beverage | $1,517.40 |
| Consulting Fee | $975.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adc Therapeutics America, INC. | $58,608.46 | 2021-2023 | |
| Beigene USA, INC. | $14,069.86 | 2022-2023 | Brukinsa |
| Seagen INC. | $4,712.05 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $233.44 | 2019-2024 | Calquence |
| E.R. Squibb & Sons, L.L.C. | $204.81 | 2022 | |
| Celgene Corporation | $194.00 | 2019-2023 | Reblozyl |
| Genzyme Corporation | $149.49 | 2023 | |
| Alexion Pharmaceuticals, INC. | $125.00 | 2023 | |
| Dova Pharmaceuticals | $99.12 | 2019 | |
| Incyte Corporation | $82.00 | 2023 | Monjuvi |
| Morphosys, US INC. | $72.50 | 2023 | Monjuvi |
| Pharmacyclics LLC, An Abbvie Company | $57.47 | 2023 | Epkinly |
| Astellas Pharma US INC | $55.86 | 2023-2024 | Xospata |
| Kyowa Kirin, INC. | $47.81 | 2023 | Poteligeo |
| Janssen Biotech, INC. | $38.85 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $21.56 | 2019 | |
| Secura Bio, INC. | $15.93 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anil Tulpule listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.